SPH Health Commerce Funding, Investors & Competitors

SPH Health Commerce has raised $228M across 2 funding rounds, most recently a $68M Series C in October 2023.

Last SPH Health Commerce funding round

$68M

Series C · Oct 2023

Cumulative funding SPH Health Commerce raised

$228M

across 2 funding rounds

Key investors in SPH Health Commerce

  • Shanghai Biomedical Industrial Equity Investment Fund
  • New Alliance Capital
  • China Reform Holdings Corporation
  • JIC Investment
  • ICBC Investment
  • Ample Harvest Finance
  • Sinocare
  • Shanghai Minority Asset Management

SPH Health Commerce Overview

About SPH Health Commerce

SPH Health Commerce is a Chinese prescription drug retailer operating under Shanghai Pharmaceuticals, founded in 2015. It runs an integrated online and offline platform for prescriptions and pharmacies, specializing in the distribution of novel medicines and clinical research products. The company has partnered with more than 300 drugmakers and connects over 40 public hospitals and 260 medical institutions to serve more than six million patients, alongside partnerships with more than 10 commercial insurance companies.


Founded

2015

HQ

ChinaChina

Status

Privately held

Customer focus

B2C

Revenue model

Product sales, Services

SPH Health Commerce Funding History

SPH Health Commerce has raised a total of $228M across 2 funding rounds.

SPH Health Commerce's first fundraising round was a $160M Series B in February 2021. The most recent completed round was a $68M Series C in October 2023.

SPH Health Commerce funding rounds

SPH Health Commerce funding rounds
DateStageInvestorsRaisedDeal Summary
Oct 2023Series CChina Reform Holdings Corporation (lead); ICBC Investment (lead); Shanghai Biomedical Industrial Equity Investment Fund$68MSPH Health Commerce is a Chinese prescription drug retailer operating under Shanghai Pharmaceuticals, founded in 2015. The company operates an integrated online and offline platform for prescriptions and pharmacies, specializing in the distribution of innovative medicines and clinical research products. SPH Health had completed a CNY1.1 billion Series A in 2015 and a CNY1 billion Series B in 2021 prior to this round. In October 2023, SPH Health closed a Series C financing round raising CNY500 million ($68.4 million USD). The round was led by Shanghai State-Owned Assets and State-owned Enterprises Comprehensive Reform Pilot Private Equity Partnership and Industrial and Commercial Bank of China Financial Asset Investment, with Shanghai Healthcare Capital also participating. According to market sources, this was one of the few fundraisers with a scale of at least CNY500 million in the Chinese primary market that year. At the time of the Series C round, SPH Health had demonstrated significant operational traction. The company had partnered with over 300 innovative drugmakers and was serving over six million patients. It achieved annual sales of over CNY3 billion and had connected more than 40 public hospitals online with 260 medical institutions. The company also maintained partnerships with over 10 commercial insurance companies. The proceeds were designated for integration of internal and external resources, mergers and acquisitions in clinical research and development, marketing of innovative medicines, and promotion of service and technological innovation to enhance accessibility of innovative drugs in China's pharmaceutical sector.
Feb 2021Series BJIC Investment (lead); Shanghai Biomedical Industrial Equity Investment Fund (lead); Huadong Industrial; Shanghai Minority Asset Management; New Alliance Capital; Sinocare; Ample Harvest Finance$160M-

Who has invested in SPH Health Commerce?

9 investors have backed SPH Health Commerce across its funding rounds, including Shanghai Biomedical Industrial Equity Investment Fund, New Alliance Capital, China Reform Holdings Corporation, JIC Investment, ICBC Investment and Ample Harvest Finance.

Lead investors include China Reform Holdings Corporation, ICBC Investment, JIC Investment and Shanghai Biomedical Industrial Equity Investment Fund.


SPH Health Commerce Investors

Investors in SPH Health Commerce by funding rounds participated
InvestorHQRoundsRoleFirst check
Shanghai Biomedical Industrial Equity Investment FundChinaGuangzhou2LeadFeb 2021
Huadong IndustrialChinaXinxiang1ParticipantFeb 2021
China Reform Holdings CorporationChinaBeijing1LeadOct 2023
ICBC InvestmentChinaNanjing1LeadOct 2023
Shanghai Minority Asset ManagementChinaShanghai1ParticipantFeb 2021
New Alliance CapitalChinaShanghai1ParticipantFeb 2021
JIC InvestmentChinaBeijing1LeadFeb 2021

This data is available for Pro users. Sign up to see all 9 SPH Health Commerce investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

SPH Health Commerce Competitors

SPH Health Commerce competitors include listed companies like GoodRx and JD Health, and private ones like Apollo Healthco, PharmEasy, Truemeds and Devoted Health.

Public and private companies comparable to SPH Health Commerce
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Apollo HealthcoIndiaIndiaPrivate-$18M$2.7B-
GoodRxUnited StatesUnited StatesPublicly listed$797M$173M$1.2B1.8x
PharmEasyIndiaMumbaiPrivate$250M-$710M-
TruemedsIndiaMumbaiPrivate$55M-$400M7.3x
JD HealthChinaChinaPublicly listed$11B$713M$14B0.6x
Devoted HealthUnited StatesBoston, MAPrivate$3.3B-$13B4.0x

SPH Health Commerce Public Comps

SPH Health Commerce is still privately-owned, but its public comps include CVS Health, Dr. Sulaiman Al Habib, Sigma Healthcare, JD Health, BrightSpring Health, Max Healthcare Institute, Oscar Health, Droga Raia, Hims and Tsuruha Holdings.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
CVS Health$402B$9.9B0.4x0.4x18.1x9.4x
Dr. Sulaiman Al Habib$3.7B$927M6.4x5.9x25.2x24.7x
Sigma Healthcare$7.7B$812M2.8x2.7x26.8x25.3x
JD Health$11B$713M0.6x0.6x9.8x8.6x
BrightSpring Health$13B$460M1.0x0.9x28.4x16.8x
Max Healthcare Institute$858M$232M12.6x10.2x46.5x36.8x
Oscar Health$12B($391M)0.5x0.4x(15.9x)12.8x
Droga Raia$8.6B$693M1.0x1.0x12.2x11.7x

This data is available for Pro users. Sign up to see all SPH Health Commerce competitors and their valuation data.

Start Free Trial

Common questions about SPH Health Commerce

When was SPH Health Commerce founded?SPH Health Commerce was founded in 2015.
Where is SPH Health Commerce headquartered?SPH Health Commerce is headquartered in China.
Is SPH Health Commerce publicly listed?No, SPH Health Commerce is a private, VC-backed company.
How much funding has SPH Health Commerce raised?SPH Health Commerce has raised $228M across 2 funding rounds.
What was SPH Health Commerce's last funding round?SPH Health Commerce's last funding round was a $68M Series C in October 2023, led by China Reform Holdings Corporation and ICBC Investment.
Who are SPH Health Commerce's investors?SPH Health Commerce's investors include Shanghai Biomedical Industrial Equity Investment Fund, Huadong Industrial, China Reform Holdings Corporation, ICBC Investment, Shanghai Minority Asset Management, New Alliance Capital, JIC Investment, Sinocare and Ample Harvest Finance.
Which companies are comparable to SPH Health Commerce?Companies comparable to SPH Health Commerce include Apollo Healthco, GoodRx, PharmEasy, Truemeds, JD Health and Devoted Health.

See companies similar to SPH Health Commerce

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial